Kam Man HUI
                       
    Main Page   Staff Directory   Publications    
                       
   
a filler
  Kam Man HUI  
 

Lab Location: Lab of Cancer Genomics, National Cancer Centre Singapore, 11 Hospital Drive, Singapore.

email:
cmrhkm@nccs.com.sg
tel: 6436-8338
 
a a a
a a a
  Key Publications  
 


Ming Shi, Min-Shan Chen, Karthik Sekar, Chee-Kiat Tan, London Lucien Ooi and Kam M Hui. 
A blood-based 3-gene signature for the non-invasive detection of early human hepatocellular carcinoma. 
European Journal of Cancer. In press. November 2013.

Ong HT, Federspiel MJ, Guo CM, Lucien Ooi L, Russell SJ, Peng KW, Hui KM.
Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
Journal of Hepatology 2013 Nov;59(5):999-1006.

Wu, Yafeng; Peng, Xue; Kang, Yuejun; and Kam M. Hui. Anal.
A paper-based microfluidic electrochemical immunodevice integrated with nanobioprobes onto graphene film for ultrasensitive multiplexed detection of cancer biomarkers. 
Anal Chem. 2013 Sep 17; 85(18):8661-8.

Xia H, Ooi LL, Hui KM.
MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Hepatology. 2013;58:629-641.

Wu Y, Xue P, Kang Y, Hui KM.
Highly specific and ultrasensitive graphene-enhanced electrochemical detection of low-abundance tumor cells using silica nanoparticles coated with antibody-conjugated quantum dots.
Anal Chem. 2013 Mar 19;85(6):3166-73.

Wang SM, Ooi LL, Hui KM. 
Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. 
Clin Cancer Res. 2011 Sep 15;17(18):6040-51.

 

 
a a a
 

    Kam Man HUI
 

Professor Hui Kam Man is currently serving as Deputy Group Director (Translational Research) at SingHealth.  He is also a Principal Investigator at the Division of Cellular and Molecular Research, National Cancer Centre Singapore.  In addition, he holds Adjunct Professorships with the Program in Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School and the Dept of Biochemistry, Yong Loo Lin School of Medicine.  Besides being a Joint Research Director at the Institute of Molecular and Cell Biology (IMCB), Prof. Hui also holds an Adjunct Senior Investigator position at the Singapore BioImaging Consortium (SBIC), A*STAR. 

Prof. Hui, a Singaporean, received his BSc and MSc from the Dept of Bacteriology & Public Health, Washington State University, Pullman, USA and his PhD in Immunology, Northwestern University School of Medicine, Chicago, U.S.A.  Prior to Singapore, Prof. Hui was employed at the Royal London Hospital, Whitechapel Road, London; and as a scientific member at the MRC National Institute for Medical Research, Mill Hill, London, United Kingdom.  Prof Hui was awarded the Fellowship of The Royal College of Pathologists, FRCPath (UK) in 2001 and the Singapore National Science Award (now the President's Science Award) in 1996 for his work in cancer genes and therapy.
 
    Human Cancer Genomics and Therapeutics
     


Primary liver cancer is the fifth most common cancer worldwide and hepatocellular carcinoma (HCC) accounts for over 85% of all primary liver cancers and hence, HCC is a worldwide health threat. The clinical management of advanced and metastatic HCC is challenging on many counts. Besides largely occurs within a background of underlying chronic liver disease and cirrhosis, HCC is a phenotypically and genetically heterogeneous polyclonal disease and resistant to most conventional chemotherapy.  Early manifestation of HCC is characteristically slow growing with few symptoms, and HCC is therefore often diagnosed at an advanced stage.  Surgery currently offers the only possibility of long-term survival for HCC patients. Unfortunately, recurrence occurs in more than two-thirds of these patients and confers a dismal prognosis. 
Despite recent advances in the prevention and treatment of human HCC, the prevalence of HCC, continues to grow.  We employ unbiased genome-wide strategies to survey relevant human HCC tissues to identify key molecular probes and genes/pathways that are altered in HCC and to explore how changes in these genes and gene regulation affect the carcinogenesis of HCC in order to learn how to manipulate these pathways to combat HCC. 

Recently, we have systematically gathered molecular evidence and provided clinical corroboration of these data to discover molecular biomarkers that, independently from clinical risk factors, can provide clinically meaningful avenues for designing strategies to decipher the underlying molecular networks leading to HCC, to diagnosis early stages of HCC and to predict treatment outcomes. Specifically,

1. We perform functional genomic studies to decipher the molecular differences between cancerous and normal liver tissues to identify novel diagnostic and prognostic biomarkers relating to human hepatocellular carcinoma.

2. To better understand the molecular roles of these biomarkers in the carcinogenesis of human hepatocellular carcinoma.

3. To design and build novel diagnostic platforms for human hepatocellular carcinoma using these novel biomarkers.

4. To design and perform animal experimentation to validate novel viral- and drug-mediated therapies for human hepatocellular carcinoma.

5. To design and generate cancer-specific vaccines for human hepatocellular carcinoma.